CorMedix Inc. (CRMD)
CorMedix Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Parsippany, NJ, US. The stock last traded at $7.22, down 1.03% on the session, giving a market capitalisation of $566.8M. On trailing twelve-month figures it carries a trailing P/E of 3.04, a net margin of 45.2%. Its beta of 1.50 implies it has historically moved more than the broad market.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CorMedix Inc. is most often compared with the following Healthcare names: